Pr Michel Ducreux
@ducreuxmichel.bsky.social
Head of the Gastrointestinal Oncology Unit. Gustave Roussy Cancer Center. Paris-Saclay University, France
Reposted by Pr Michel Ducreux
🙌 The ESMO GI Congress 2025 is live — in Barcelona, and online! #ESMOGI25 brings global experts together to advance GI oncology from 2–5 July. Let’s get started!
🔗 buff.ly/5V8eZ1m
🔗 buff.ly/5V8eZ1m
July 2, 2025 at 11:03 AM
🙌 The ESMO GI Congress 2025 is live — in Barcelona, and online! #ESMOGI25 brings global experts together to advance GI oncology from 2–5 July. Let’s get started!
🔗 buff.ly/5V8eZ1m
🔗 buff.ly/5V8eZ1m
Reposted by Pr Michel Ducreux
#ESMOGI25: New combinations show promise in #HCC. Favourable responses were seen with irpagratinib plus atezolizumab in FGF19+ disease. STRIDE had acceptable safety in poor-prognosis patients in the SIERRA #ClinicalTrial.
Read the #ESMODailyReporter
🔗 ow.ly/Nxug50WjJIJ
Read the #ESMODailyReporter
🔗 ow.ly/Nxug50WjJIJ
July 2, 2025 at 2:30 PM
#ESMOGI25: New combinations show promise in #HCC. Favourable responses were seen with irpagratinib plus atezolizumab in FGF19+ disease. STRIDE had acceptable safety in poor-prognosis patients in the SIERRA #ClinicalTrial.
Read the #ESMODailyReporter
🔗 ow.ly/Nxug50WjJIJ
Read the #ESMODailyReporter
🔗 ow.ly/Nxug50WjJIJ
Reposted by Pr Michel Ducreux
#ESMOGI25: A combination of givastomig, nivolumab and mFOLFOX shows promising activity and acceptable safety in HER2− CLDN18.2+ #GastroEsophagealCancer, regardless of #PDL1 or CLDN18.2 status.
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
July 2, 2025 at 3:10 PM
#ESMOGI25: A combination of givastomig, nivolumab and mFOLFOX shows promising activity and acceptable safety in HER2− CLDN18.2+ #GastroEsophagealCancer, regardless of #PDL1 or CLDN18.2 status.
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
Further details in the #ESMODailyReporter
🔗 buff.ly/hKBZtJZ
Reposted by Pr Michel Ducreux
June is #UterineCancerAwareness month.
A study presented at #ESMOGynae25 on #EndometrialCancer reveals that molecular subtyping using IHC + NGS identifies targetable alterations, influencing treatment. Results highlight the need for advanced diagnostics and updated guidelines.
A study presented at #ESMOGynae25 on #EndometrialCancer reveals that molecular subtyping using IHC + NGS identifies targetable alterations, influencing treatment. Results highlight the need for advanced diagnostics and updated guidelines.
June 26, 2025 at 2:31 PM
June is #UterineCancerAwareness month.
A study presented at #ESMOGynae25 on #EndometrialCancer reveals that molecular subtyping using IHC + NGS identifies targetable alterations, influencing treatment. Results highlight the need for advanced diagnostics and updated guidelines.
A study presented at #ESMOGynae25 on #EndometrialCancer reveals that molecular subtyping using IHC + NGS identifies targetable alterations, influencing treatment. Results highlight the need for advanced diagnostics and updated guidelines.
Reposted by Pr Michel Ducreux
📣 Get ready to submit your research to EMUC25!
⏰ Abstract deadline coming up: 1 August 2025.
🔗 buff.ly/leSW7AP
⏰ Abstract deadline coming up: 1 August 2025.
🔗 buff.ly/leSW7AP
June 27, 2025 at 6:01 AM
📣 Get ready to submit your research to EMUC25!
⏰ Abstract deadline coming up: 1 August 2025.
🔗 buff.ly/leSW7AP
⏰ Abstract deadline coming up: 1 August 2025.
🔗 buff.ly/leSW7AP
Reposted by Pr Michel Ducreux
HCC micro learning 🎓
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
The expanding role of immunotherapy in HCC | COR2ED
In this micro learning developed by experts Prof. Aiwu Ruth He and Prof. Beau Toskich, you’ll learn about the expanding role of immunotherapy (IO) in
cor2ed.com
May 19, 2025 at 3:36 PM
HCC micro learning 🎓
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
FLOT + durvalumab new perioperative treatment of localised gastric cancer
June 1, 2025 at 8:24 PM
FLOT + durvalumab new perioperative treatment of localised gastric cancer
Reposted by Pr Michel Ducreux
Every day during #ASCO25, Dr. John Sweetenham will offer concise expert analysis on some of the day's top abstracts on the #ASCODailyNews Podcast. Listen to today's episode on Day 1 and check back daily at 4:30pm CT for more: dailynews.ascopubs.org/do/podcast-d... #oncsky
May 30, 2025 at 11:42 PM
Every day during #ASCO25, Dr. John Sweetenham will offer concise expert analysis on some of the day's top abstracts on the #ASCODailyNews Podcast. Listen to today's episode on Day 1 and check back daily at 4:30pm CT for more: dailynews.ascopubs.org/do/podcast-d... #oncsky
Reposted by Pr Michel Ducreux
DYNAMIC-III:
🩸27% of stage III CRC are ctDNA pos
➡️ ctDNA is prognostic but not predictive for adjuvant chemo escalation
#ASCO25 @ascocancer.bsky.social
🩸27% of stage III CRC are ctDNA pos
➡️ ctDNA is prognostic but not predictive for adjuvant chemo escalation
#ASCO25 @ascocancer.bsky.social
May 30, 2025 at 9:02 PM
DYNAMIC-III:
🩸27% of stage III CRC are ctDNA pos
➡️ ctDNA is prognostic but not predictive for adjuvant chemo escalation
#ASCO25 @ascocancer.bsky.social
🩸27% of stage III CRC are ctDNA pos
➡️ ctDNA is prognostic but not predictive for adjuvant chemo escalation
#ASCO25 @ascocancer.bsky.social
Confirmation of the pronostic role of positive ctDNA in resected colon cancer... a large US study
May 30, 2025 at 9:08 PM
Confirmation of the pronostic role of positive ctDNA in resected colon cancer... a large US study
ASCO meeting starting today in Chicago
May 30, 2025 at 7:34 PM
ASCO meeting starting today in Chicago
Reposted by Pr Michel Ducreux
The rate of dementia caused by Alzheimer’s disease and other conditions is rising rapidly in China and will remain high if preventive measures are not taken
https://go.nature.com/43ktPB5
https://go.nature.com/43ktPB5
China’s dementia incidence is rising fast ― outpacing the global average
Nature - Public-health measures to curb high blood-sugar levels, smoking and obesity could help to rein in the trend.
go.nature.com
May 17, 2025 at 6:46 AM
The rate of dementia caused by Alzheimer’s disease and other conditions is rising rapidly in China and will remain high if preventive measures are not taken
https://go.nature.com/43ktPB5
https://go.nature.com/43ktPB5
Reposted by Pr Michel Ducreux
📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines
🔗https://buff.ly/Mybc2Nq
@ducreuxmichel.bsky.social
🔗https://buff.ly/Mybc2Nq
@ducreuxmichel.bsky.social
April 9, 2025 at 8:26 AM
📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines
🔗https://buff.ly/Mybc2Nq
@ducreuxmichel.bsky.social
🔗https://buff.ly/Mybc2Nq
@ducreuxmichel.bsky.social
Reposted by Pr Michel Ducreux
📰 Des femmes affrontent leur "risque augmenté" de #cancer du sein grâce à la prévention personnalisée.
Découvrez le programme #Interception proposé à @gustaveroussy.fr, dans une dépêche @afpfr.bsky.social publiée dans @sciencesetavenir.bsky.social ⤵
Découvrez le programme #Interception proposé à @gustaveroussy.fr, dans une dépêche @afpfr.bsky.social publiée dans @sciencesetavenir.bsky.social ⤵
Des femmes affrontent leur "risque augmenté" de cancer du sein grâce à la prévention personnalisée
Des femmes affrontent leur "risque augmenté" de cancer du sein grâce à la prévention personnalisée
www.sciencesetavenir.fr
March 24, 2025 at 1:33 PM
📰 Des femmes affrontent leur "risque augmenté" de #cancer du sein grâce à la prévention personnalisée.
Découvrez le programme #Interception proposé à @gustaveroussy.fr, dans une dépêche @afpfr.bsky.social publiée dans @sciencesetavenir.bsky.social ⤵
Découvrez le programme #Interception proposé à @gustaveroussy.fr, dans une dépêche @afpfr.bsky.social publiée dans @sciencesetavenir.bsky.social ⤵
Reposted by Pr Michel Ducreux
Kicking off #CCEAM25 at @nkinl.bsky.social! Looking forward to two days of collaboration, networking, and insightful discussions.
@vhio.bsky.social @nct-heidelberg.bsky.social @dkfz.bsky.social @gustaveroussy.fr @ki.se
@crukcamcentre.bsky.social
@vhio.bsky.social @nct-heidelberg.bsky.social @dkfz.bsky.social @gustaveroussy.fr @ki.se
@crukcamcentre.bsky.social
March 10, 2025 at 4:57 PM
Kicking off #CCEAM25 at @nkinl.bsky.social! Looking forward to two days of collaboration, networking, and insightful discussions.
@vhio.bsky.social @nct-heidelberg.bsky.social @dkfz.bsky.social @gustaveroussy.fr @ki.se
@crukcamcentre.bsky.social
@vhio.bsky.social @nct-heidelberg.bsky.social @dkfz.bsky.social @gustaveroussy.fr @ki.se
@crukcamcentre.bsky.social
Reposted by Pr Michel Ducreux
Our study is now out in JCO print edition!
There's still something special to getting to hold a physical copy of what you did. Gotta take your wins where you can, these days.
Full article here:
ascopubs.org/doi/full/10....
@ascocancer.bsky.social
There's still something special to getting to hold a physical copy of what you did. Gotta take your wins where you can, these days.
Full article here:
ascopubs.org/doi/full/10....
@ascocancer.bsky.social
February 20, 2025 at 9:40 PM
Our study is now out in JCO print edition!
There's still something special to getting to hold a physical copy of what you did. Gotta take your wins where you can, these days.
Full article here:
ascopubs.org/doi/full/10....
@ascocancer.bsky.social
There's still something special to getting to hold a physical copy of what you did. Gotta take your wins where you can, these days.
Full article here:
ascopubs.org/doi/full/10....
@ascocancer.bsky.social
Reposted by Pr Michel Ducreux
We are committed to advancing policies that improve patient access to high-quality cancer care. We continue to collaborate with all stakeholders to address existing barriers and ultimately improve cancer care for those in need.
‘Lose-lose-lose’ scenario: ASCO seeks reduced out-of-pocket costs for cancer care
Out-of-pocket costs like deductibles and copays deter people with cancer from complying with treatment.This creates a “lose-lose-lose” scenario for patients, payers and employers, Clifford...
www.healio.com
February 21, 2025 at 2:37 PM
We are committed to advancing policies that improve patient access to high-quality cancer care. We continue to collaborate with all stakeholders to address existing barriers and ultimately improve cancer care for those in need.
Reposted by Pr Michel Ducreux
In the past two decades, substantial advancements have been made in cancer research and care.
From innovative treatments to improving access to care globally, discover how oncology research is shaping the future of cancer care.
🎥 tinyurl.com/5a642pwk #OncSky #MedSky
From innovative treatments to improving access to care globally, discover how oncology research is shaping the future of cancer care.
🎥 tinyurl.com/5a642pwk #OncSky #MedSky
February 21, 2025 at 2:34 PM
In the past two decades, substantial advancements have been made in cancer research and care.
From innovative treatments to improving access to care globally, discover how oncology research is shaping the future of cancer care.
🎥 tinyurl.com/5a642pwk #OncSky #MedSky
From innovative treatments to improving access to care globally, discover how oncology research is shaping the future of cancer care.
🎥 tinyurl.com/5a642pwk #OncSky #MedSky
Reposted by Pr Michel Ducreux
🚀 We have launched our 1st Clinical Series of 2025 at the EASL Liver Cancer Summit 2025 in Paris! 𝐁𝐢𝐥𝐢𝐚𝐫𝐲 𝐓𝐫𝐚𝐜𝐭 𝐂𝐚𝐧𝐜𝐞𝐫𝐬 (BTCs)
🔬BTCs are rising in incidence & mortality across Europe.
Explore key findings & recommendations in our infographic & read the Series here
thelancet.com/infographics...
🔬BTCs are rising in incidence & mortality across Europe.
Explore key findings & recommendations in our infographic & read the Series here
thelancet.com/infographics...
February 20, 2025 at 3:34 PM
🚀 We have launched our 1st Clinical Series of 2025 at the EASL Liver Cancer Summit 2025 in Paris! 𝐁𝐢𝐥𝐢𝐚𝐫𝐲 𝐓𝐫𝐚𝐜𝐭 𝐂𝐚𝐧𝐜𝐞𝐫𝐬 (BTCs)
🔬BTCs are rising in incidence & mortality across Europe.
Explore key findings & recommendations in our infographic & read the Series here
thelancet.com/infographics...
🔬BTCs are rising in incidence & mortality across Europe.
Explore key findings & recommendations in our infographic & read the Series here
thelancet.com/infographics...
Reposted by Pr Michel Ducreux
Urgent action is needed to scale-up cancer prevention and care services.
Cancer registries can play a crucial role in this.
Ahead of #WorldCancerDay, our Editorial explores the benefits and challenges of cancer registries in global cancer care: tinyurl.com/ywpr6e37
Cancer registries can play a crucial role in this.
Ahead of #WorldCancerDay, our Editorial explores the benefits and challenges of cancer registries in global cancer care: tinyurl.com/ywpr6e37
January 31, 2025 at 3:31 PM
Urgent action is needed to scale-up cancer prevention and care services.
Cancer registries can play a crucial role in this.
Ahead of #WorldCancerDay, our Editorial explores the benefits and challenges of cancer registries in global cancer care: tinyurl.com/ywpr6e37
Cancer registries can play a crucial role in this.
Ahead of #WorldCancerDay, our Editorial explores the benefits and challenges of cancer registries in global cancer care: tinyurl.com/ywpr6e37
Reposted by Pr Michel Ducreux
🔴 Eduardo Terán, from VHIO's Upper Gastrointestinal & Endocrine Tumor Group, presented the poster "Molecular profiling of a gastroesophageal adenocarcinoma multicohort using next-generation sequencing" at #ASCOGI. 🩺🔬
January 24, 2025 at 8:32 PM
🔴 Eduardo Terán, from VHIO's Upper Gastrointestinal & Endocrine Tumor Group, presented the poster "Molecular profiling of a gastroesophageal adenocarcinoma multicohort using next-generation sequencing" at #ASCOGI. 🩺🔬
Reposted by Pr Michel Ducreux
New research just presented at #GI25: BREAKWATER study finds 1L EC + mFOLFOX6 improves outcomes in BRAFV600E-mutant mCRC, offering new SOC: brnw.ch/21wQfxm
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
January 25, 2025 at 10:29 PM
New research just presented at #GI25: BREAKWATER study finds 1L EC + mFOLFOX6 improves outcomes in BRAFV600E-mutant mCRC, offering new SOC: brnw.ch/21wQfxm
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
Nivolumab + Ipilimumab better than nivoluma in the treatment of metastatic MSI patients. Results presented by T André at GI ASCO. Significant improvement in PFS
January 25, 2025 at 10:04 PM
Nivolumab + Ipilimumab better than nivoluma in the treatment of metastatic MSI patients. Results presented by T André at GI ASCO. Significant improvement in PFS
Aspirin 160 mg daily reduced by 50% the recurrence rate of colorectal cancer patients with PI3K mutated tumours
January 25, 2025 at 5:57 PM
Aspirin 160 mg daily reduced by 50% the recurrence rate of colorectal cancer patients with PI3K mutated tumours
Reposted by Pr Michel Ducreux
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: brnw.ch/21wQeCg
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
January 24, 2025 at 9:33 PM
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: brnw.ch/21wQeCg
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM